Cardiff Oncology, Inc.: directors' dealings · United States · SEC (Form 4)

About Cardiff Oncology, Inc.

Cardiff Oncology, Inc. is a U.S.-listed clinical-stage biotechnology company traded on the Nasdaq under the ticker CRDF. The company is headquartered in San Diego, California, United States, and traces its corporate roots back to 1999 before evolving into its current oncology-focused strategy. For international investors, Cardiff Oncology fits the profile of a development-stage U.S. biotech: valuation is primarily driven by clinical progress, regulatory milestones, and capital needs rather than current commercial revenues. The company’s core asset is onvansertib, an orally administered, highly selective PLK1 (Polo-Like Kinase 1) inhibitor. PLK1 is a validated oncology target, and Cardiff’s strategy is to enhance standard-of-care regimens in difficult-to-treat cancers by combining onvansertib with existing therapies. This approach is intended to create clinical differentiation without requiring a completely novel backbone regimen. The lead development program is focused on first-line RAS-mutated metastatic colorectal cancer (mCRC), where onvansertib is being evaluated in combination with standard regimens such as FOLFIRI/bevacizumab or FOLFOX/bevacizumab. Beyond colorectal cancer, the company has also described investigator-initiated or exploratory studies in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, triple-negative breast cancer, and chronic myelomonocytic leukemia. In competitive terms, Cardiff operates in a crowded oncology innovation landscape dominated by larger biotech and pharmaceutical companies with greater capital resources, broader pipelines, and more established commercial infrastructure. Its competitive edge depends on the biology of PLK1 inhibition, the oral profile of onvansertib, and the ability to show meaningful efficacy in biomarker-defined patient subsets. Recent developments have been centered on positive Phase 2 data from the CRDF-004 trial in first-line RAS-mutated mCRC, with updates released in 2025 and further business updates in January 2026 and May 2026. The company also announced leadership changes in 2026 as it transitions toward later-stage clinical development and key corporate milestones. Cardiff’s recent disclosures indicate that the next phase of value creation will depend on confirming durability of response, translating trial data into a registrational strategy, and managing the financing requirements typical of a clinical-stage biotech. For investors, the opportunity is substantial, but so is the binary clinical risk inherent to a single-asset platform company.